Literature DB >> 10675753

Isolation and characterization of human multiple myeloma cell enriched populations.

Y T Tai1, G Teoh, Y Shima, D Chauhan, S P Treon, N Raje, T Hideshima, F E Davies, K C Anderson.   

Abstract

We developed a simple and rapid method to enrich tumor cells within bone marrow (BM) aspirates from patients with multiple myeloma (MM). Thirty patients with a median of 50% (8-85%) MM cells by morphology and 55% (6--85%) MM cells identified by CD38+CD45-cell surface phenotype were studied. BM mononuclear cells (BMMCs) were isolated by Ficoll Hypaque sedimentation and incubated with a cocktail of mouse monoclonal antibodies (mAbs) directed against CD3 (T cells); CD11b and CD14 (monocytes); CD33 (myeloid cells), CD45 and CD45RA (leucocyte common antigen); CD32 as well as glycophorin A. After the addition of anti-mouse Fc Ig-coated immunomagnetic beads, mAb-bound cells were removed in a magnetic field. The residual cell populations were enriched for MM cells, evidenced by >95% plasma cell morphology and >95% CD38+CD45RA-cell surface phenotype. Since this method requires only two short incubations, cell losses were minimal and the yield of MM cells was therefore high (>95%). Viability of the MM-cell enriched fractions was 99%, and these cells were functional in assays of proliferation, cell cycle analysis and immunoglobulin secretion. This immunomagnetic bead depletion method therefore permits the ready isolation of homogeneous populations of patient MM cells for use in both cellular and molecular studies.

Entities:  

Mesh:

Year:  2000        PMID: 10675753     DOI: 10.1016/s0022-1759(99)00199-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

Review 1.  Optimal molecular profiling of tissue and tissue components: defining the best processing and microdissection methods for biomedical applications.

Authors:  G Steven Bova; Isam A Eltoum; John A Kiernan; Gene P Siegal; Andra R Frost; Carolyn J M Best; John W Gillespie; Gloria H Su; Michael R Emmert-Buck
Journal:  Mol Biotechnol       Date:  2005-02       Impact factor: 2.695

2.  Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Authors:  Triona Ni Chonghaile; Kristopher A Sarosiek; Thanh-Trang Vo; Jeremy A Ryan; Anupama Tammareddi; Victoria Del Gaizo Moore; Jing Deng; Kenneth C Anderson; Paul Richardson; Yu-Tzu Tai; Constantine S Mitsiades; Ursula A Matulonis; Ronny Drapkin; Richard Stone; Daniel J Deangelo; David J McConkey; Stephen E Sallan; Lewis Silverman; Michelle S Hirsch; Daniel Ruben Carrasco; Anthony Letai
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

3.  Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

Authors:  Noopur Raje; Shaji Kumar; Teru Hideshima; Aldo Roccaro; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Dharminder Chauhan; Nikhil C Munshi; Simon R Green; Kenneth C Anderson
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

4.  Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

Authors:  Renate Burger; Steven Le Gouill; Yu-Tzu Tai; Reshma Shringarpure; Pierfrancesco Tassone; Paola Neri; Klaus Podar; Laurence Catley; Teru Hideshima; Dharminder Chauhan; Eian Caulder; Claire L Neilan; Kris Vaddi; Jun Li; Martin Gramatzki; Jordan S Fridman; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

5.  Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

Authors:  D Cirstea; T Hideshima; L Santo; H Eda; Y Mishima; N Nemani; Y Hu; N Mimura; F Cottini; G Gorgun; H Ohguchi; R Suzuki; H Loferer; N C Munshi; K C Anderson; N Raje
Journal:  Leukemia       Date:  2013-06-28       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.